Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article (93)

Advertisement

Research Article Free access | 10.1172/JCI116642

Angiotensin II increases glucose utilization during acute hyperinsulinemia via a hemodynamic mechanism.

T A Buchanan, H Thawani, W Kades, J G Modrall, F A Weaver, C Laurel, R Poppiti, A Xiang, and W Hsueh

Department of Medicine, Los Angeles County-University of Southern California Medical Center.

Find articles by Buchanan, T. in: PubMed | Google Scholar

Department of Medicine, Los Angeles County-University of Southern California Medical Center.

Find articles by Thawani, H. in: PubMed | Google Scholar

Department of Medicine, Los Angeles County-University of Southern California Medical Center.

Find articles by Kades, W. in: PubMed | Google Scholar

Department of Medicine, Los Angeles County-University of Southern California Medical Center.

Find articles by Modrall, J. in: PubMed | Google Scholar

Department of Medicine, Los Angeles County-University of Southern California Medical Center.

Find articles by Weaver, F. in: PubMed | Google Scholar

Department of Medicine, Los Angeles County-University of Southern California Medical Center.

Find articles by Laurel, C. in: PubMed | Google Scholar

Department of Medicine, Los Angeles County-University of Southern California Medical Center.

Find articles by Poppiti, R. in: PubMed | Google Scholar

Department of Medicine, Los Angeles County-University of Southern California Medical Center.

Find articles by Xiang, A. in: PubMed | Google Scholar

Department of Medicine, Los Angeles County-University of Southern California Medical Center.

Find articles by Hsueh, W. in: PubMed | Google Scholar

Published August 1, 1993 - More info

Published in Volume 92, Issue 2 on August 1, 1993
J Clin Invest. 1993;92(2):720–726. https://doi.org/10.1172/JCI116642.
© 1993 The American Society for Clinical Investigation
Published August 1, 1993 - Version history
View PDF
Abstract

To determine whether hemodynamic changes can modulate insulin action in vivo, we administered angiotensin II (AII) to normal men under three separate, euglycemic conditions. First, in the presence of physiological hyperinsulinemia (approximately 115 microU/ml), infusion of AII at rates of 2, 10, and 20 ng/min per kg caused significant elevations of blood pressure, whole-body glucose clearance, and plasma insulin concentrations in an AII dose-dependent manner. Second, in the presence of plasma insulin concentrations that stimulate glucose transport maximally (approximately 5,000 microU/ml), AII infusions increased whole-body glucose clearance without enhancing glucose extraction across the leg. Third, in the presence of basal insulin concentrations (approximately 13 microU/ml), AII infusions had no effect on whole-body glucose turnover or leg glucose extraction. Thus, AII enhanced whole-body glucose utilization without directly stimulating glucose transport in a major skeletal muscle bed. To evaluate a possible hemodynamic mechanism for the effects of AII on glucose utilization, we measured blood flow to two areas that differ in their sensitivity to insulin: the kidneys and the leg. We found that AII redistributed blood flow away from the predominantly insulin-independent tissues of the kidney and toward the insulin-sensitive tissues of the leg during both sham and hyperinsulinemic glucose clamps. The redistribution of flow had no effect on whole-body glucose turnover when leg glucose uptake was unstimulated (sham clamps). However, when leg glucose uptake was activated by insulin, the redistribution of flow caused a net increase in whole-body glucose utilization. Our findings indicate that hemodynamic factors can modulate insulin action in vivo. Furthermore, our results suggest that variable activity of the renin-angiotensin system may contribute to inconsistencies in the association between insulin resistance and hypertension.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 720
page 720
icon of scanned page 721
page 721
icon of scanned page 722
page 722
icon of scanned page 723
page 723
icon of scanned page 724
page 724
icon of scanned page 725
page 725
icon of scanned page 726
page 726
Version history
  • Version 1 (August 1, 1993): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article (93)

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts